Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1354

ARX517-hIgG1

Home » Antibodies » ARX517-hIgG1

Background of ARX517-hIgG1

Prostate cancer is the most prevalent cancer and the second leading cause of cancer-related deaths among men in the United States. Metastatic castration-resistant prostate cancer (mCRPC) is an advanced stage of the disease, characterized by the failure of androgen-deprivation therapies and a low survival rate. Recently, the prostate-specific membrane antigen (PSMA) has been identified as a tumor antigen in prostate cancer, showing high expression in tumors and low expression in normal tissues. Ambrx has developed ARX517, an engineered precision biologic (EPB) that utilizes an expanded genetic code. ARX517 is an anti-PSMA targeted next-generation antibody drug conjugate (ADC) designed for the treatment of mCRPC patients. It consists of a humanized anti-PSMA antibody that is specifically conjugated to the drug linker AS269, a potent tubulin inhibitor. This results in a drug-to-antibody ratio of 2. Once ARX517 binds to PSMA on the surface of tumor cells, it is internalized and releases a cytotoxic payload that inhibits tubulin polymerization and induces cellular apoptosis.

Specifications

Catalog Number:
KB-1354
Antibody Name:
ARX517-hIgG1
Isotype:
Human IgG1,kappa
FC Muations:
Target:
PSMA
Species Reactivity:
Human
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
50 mM sodium citrate,150mM NaCl,pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
ELISA
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. hen J, Pachynski R, Nordquist LT, et al. APEX-01: First-in-human phase I/II study of ARX517 an anti- prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol. 2023;34(suppl 2):S974-S975. doi:10.1016/j.annonc.2023.09.2752
  2. FDA grants Fast Track Designation for Ambrx’s ARX517 for the treatment of metastatic castration-resistant prostate cancer. News release. Ambrx Biopharma Inc. July 19, 2023. Accessed October 25, 2023.